Drug Interaction Report

Glyburide and Encorafenib: Interaction Details

A pharmacist-reviewed analysis of the Glyburide and Encorafenib interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Encorafenib

Braftovi Braftovi®
+

Glyburide

DiaBeta® Glynase Glynase® Micronase®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Moderate
Can be significant — usually manageable with monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 79 documented Glyburide interactions, 37 are rated moderate — including this one.
Onset
unspecified
Evidence
theoretical
Severity
Moderate

What happens

Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities and increased risk of OATP1B3 substrate-related toxicities

Interaction Deep Dive

Concomitant administration of encorafenib (an inhibitor of OATP1B1 and OATP1B3) with a substrate of OATP1B1 and OATP1B3 may increase OATP1B1 and OATP1B3 substrates exposure and increase risk of OATP1B1 and OATP1B3 substrate-related toxicities. When used concomitantly, monitor for signs and symptoms of increased substrate exposure and consider adjusting the substrate dose of these substrates. In a drug interaction study, repeated doses of encorafenib 450 mg once daily and binimetinib 45 mg twice daily with a single dose of rosuvastatin (a sensitive substrate of OATP1B1 and OATP1B3) increased rosuvastatin Cmax by 2.7-fold and AUC by 1.6-fold1.

Why it happens (mechanism)

Inhibition of OATP1B1-mediated efflux transport by encorafenib; inhibition of OATP1B3-mediated efflux transport by encorafenib

Literature reports

1 report — tap to read

a) In a drug interaction study, repeated doses of encorafenib 450 mg once daily and binimetinib 45 mg twice daily with a single dose of rosuvastatin (a sensitive substrate of OATP1B1 and OATP1B3) increased rosuvastatin Cmax by 2.7-fold and AUC by 1.6-fold 1.

Common questions

Can I take Glyburide and Encorafenib together?

Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities and increased risk of OATP1B3 substrate-related toxicities Always confirm with your pharmacist or prescriber before making any change.

How serious is the Glyburide and Encorafenib interaction?

It is rated moderate. Can be significant — usually manageable with monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Glyburide or Encorafenib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there anything you'd monitor while I'm on both?

References (1)

  1. Product Information: BRAFTOVI(R) oral capsules, encorafenib oral capsules. Array BioPharma Inc (per FDA), Boulder, CO, 2024. DailyMed
Was this write-up helpful?
Encorafenib

Keep reading about Encorafenib

All Encorafenib interactions (468) Encorafenib drug information
Also serious with: Piperaquine Posaconazole Pimozide Doravirine
Glyburide

Keep reading about Glyburide

All Glyburide interactions (79) Glyburide drug information
Also serious with: Moxifloxacin Ophthalmic Disopyramide Belumosudil Orlistat
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Encorafenib + Activated Charcoal American Hellebore Arsenic Cesium Ephedra Grapefruit Sida Cordifolia St. John's Wort + 143 more
Glyburide + Activated Charcoal Apple Beer Grapefruit Siberian Cocklebur Sweet Orange Wine Acai + 323 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.